

Programme update: Accelerated Vaccine Introduction (AVI)

Jon Pearman

*GAVI Alliance Board Meeting
Washington DC, USA, 12-13 June 2012*



AVI update


Rotavirus & Pneumococcal vaccines - status of roll out & supply



AVI TAC

BILL & MELINDA
GATES foundation


Pneumococcal vaccine - unconstrained annual introductions



Source: GAVI Strategic Demand Forecast v5.0

GAVI Alliance Board Meeting
Washington DC, 13-14 June 2012


Pneumococcal vaccine - supply constrained annual introductions



Source: GAVI Strategic Demand Forecast v5.0


GAVI Alliance Board Meeting
Washington DC, 13-14 June 2012

Pneumococcal vaccine: cumulative introductions versus 2011–2015 Strategy




- 16 roll-outs in 2011
- 10 roll-outs in 2012
- Currently predict 5 will introduce in 2013
- 2014-15 will see intros back on track
- Delays of a year effecting up to 15 countries
- Readiness continues to be potential bottleneck

Pneumococcal vaccine: forecast demand (millions of doses per year)




Pneumococcal vaccine: demand and supply (millions of doses per year)



Factors influencing the difference in supply and demand?

- Increases in supply
 - Additional supply recently confirmed in writing
 - Working to confirm indications of further increases
- Slower roll out
 - Unavoidable delays in launch date in 2012 means some doses roll over to 2013
 - Large country readiness in 2013 being assessed
 - Analysis in launched countries to predict rate of ramp up
- Net gap likely to be reduced by 80%
 - 60% from supply increase, 40% by readiness


Rotavirus vaccine - unconstrained annual introductions



* Source demand forecast v5.0

GAVI Alliance Board Meeting
Washington DC, 13-14 June 2012


Rota: supply constrained annual introductions



* Source demand forecast v5.0


GAVI Alliance Board Meeting
Washington DC, 13-14 June 2012

Rotavirus vaccine: cumulative introductions versus 2011–2015 Strategy



- 8 roll-outs in 2012
- Currently predict 2-5 will introduce in 2013
- 2014-15 will see intros back on track
- Up to 9 approved countries delayed for a year
- Readiness continues to be potential bottleneck

Demand & supply in doses operational forecast



Factors influencing the difference in supply and demand?

- Scale up issues reducing doses in 2012
- Supply increases from 2013
 - capacity increase Q4, subject to reaching milestones at supplier & regulatory agencies
 - Possible additional supply of alternate product presentation, feasibility with countries being reviewed, and financial implications
- Predicting demand
 - Analysis of ramp up assumptions in large countries
 - Consideration of 3 versus 2 dose schedule for Rotarix
- Net supply gap - pending further information
 - Increased capacity by 2014, but need new contracts

Pipeline for increased capacity

■ **Pneumococcal vaccine**

- Increased capacity from existing suppliers
- 2 potential new suppliers ~ 2016+
- Potential low multi-dose vial developments from existing MNC ~ 2016

■ **Rotavirus vaccine**

- Increased capacity from existing suppliers
- Improved formulation from MNC ~ 2015+
- 2 emerging market suppliers ~ 2015+

Conclusion

- All efforts being made to increase supply
- Number of children vaccinated with pneumo and rota will be impacted
- Active management of readiness, roll-out and scale up



www.gavialliance.org